Suda Pharmaceuticals Ltd organizacji EPS
Jaka jest wartość EPS organizacji Suda Pharmaceuticals Ltd?
Wartość EPS organizacji Suda Pharmaceuticals Ltd to -0.02
Jaka jest definicja EPS?
Zysk na akcję (EPS) to zysk spółki na jedną akcję. Jest dostosowywany do rozcieńczenia i obliczany w ciągu dwunastu miesięcy.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
EPS firm w Health Care sektor na ASX w porównaniu do Suda Pharmaceuticals Ltd
Czym się zajmuję organizacja Suda Pharmaceuticals Ltd?
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Firmy z eps podobne do Suda Pharmaceuticals Ltd
- Wartość EPS organizacji Fountainhall Capital Corp to -0.02
- Wartość EPS organizacji Hong Kong Television Network to -0.02
- Wartość EPS organizacji China Sandi to -0.02
- Wartość EPS organizacji BExcellent to -0.02
- Wartość EPS organizacji Gitennes Exploration Inc to -0.02
- Wartość EPS organizacji Horizon Gold to -0.02
- Wartość EPS organizacji Suda Pharmaceuticals Ltd to -0.02
- Wartość EPS organizacji Collaborate to -0.02
- Wartość EPS organizacji Kelso Technologies to -0.02
- Wartość EPS organizacji Shen You to -0.02
- Wartość EPS organizacji China NT Pharma to -0.02
- Wartość EPS organizacji Leyou Technologies to -0.02
- Wartość EPS organizacji Newmac Resources to -0.02